A B S T R A C T Porcine intestinal mucosal heparin induced aggregation of platelets in citrated platelet-rich plasma and enhanced platelet aggregation and serotonin secretion induced by other agents. This action ofheparin was blocked by substances that elevate platelet cyclic AMP and by EDTA but not by inhibitors of platelet cyclooxygenase. The effect was not inhibited by apyrase or by N-amylthio-5'-AMP and therefore did not require the action of ADP, nor was there activation of platelet phospholipase. Platelet aggregation by heparin required a plasma cofactor different from the cofactor required for ristocetin.
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Fractionation of heparin yielded preparations that varied in molecular weight and, within a given molecular weight fraction, in affinity for antithrombin III.
Fractions of high molecular weight (average 20,000) were more reactive with platelets than were fractions of low molecular weight (7, 000) . Anticoagulant activity did not parallel the platelet reactivity of heparin fractions. Among high molecular weight fractions, preparations of high or low antithrombin affinity were equally active in induction of platelet aggregation. In low molecular weight fractions, there was an inverse relationship between platelet reactivity and anticoagulant activity in normal platelet-rich plasma, but, in plateletrich plasma depleted of antithrombin, low molecular weight fractions of high and low antithrombin affinity reacted equally with platelets. These results suggest that formation of an antithrombin-heparin complex protected platelets from aggregation by heparin.
Selection of heparin fractions of low molecular weight and high antithrombin affinity may improve anticoagulant therapy and development of thromboresistant heparin-coated artificial materials.
INTRODUCTION
The anticoagulant action of heparin results from its ability to bind and activate a natural inhibitor of the serine proteases involved in the intrinsic coagulation system, so-called "antithrombin III," or "heparin cofactor" (1) . Heparin also blocks the action of thrombin on platelets, but many other activities of platelets proceed despite the administration of heparin. The drug does not prevent platelet consumption during extracorporeal circulation for cardiopulmonary bypass (2) or hemodialysis (3) , nor does it prevent adherence of platelets to subendothelial connective tissue (4) or to artificial surfaces in vitro (5, 6) . Administration of heparin leads sometimes to thrombocytopenia (7) (8) (9) (10) (11) (12) (13) (14) , and there are claims that arterial embolization has been induced by heparin (15) (16) (17) . Artificial materials with heparin bonded to the surface in an attempt to prevent thrombotic complications ofprosthetic devices have been erratic in their performance (2, (18) (19) (20) (21) ; even optimistic accounts (22) describe a profound shortening ofplatelet survival.
In vitro, heparin has been reported to reduce, enhance, or have no effect on platelet aggregation, depending on the system employed for studying it. O'Brien et al. (23) Besterman et al. (24) , and Gillett et al. (25) found reduced platelet aggregation and serotonin release by epinephrine and collagen in heparinized platelet-rich plasma (PRP)' but it was later suggested (26, 27 ) that this may have resulted from a partial and incomplete response ofthe platelets having already occurred. Eika (28) reported that platelets washed and suspended in a buffer were aggregated by high concinArations of heparin and, together with Thomson lower concentrations. Lindsay et al. (18) described enhancement of platelet aggregation during extracorporeal circulation with a heparin-coated circuit, presumably attributable to the action of desorbed heparin, although they claimed a reduction in reactivity of the sturface itself as a result of heparin binding.
A possible explanation for the varied results in differenit laboratories was suggested by Lam et al. (31) , who reported that heparin is a heterogeneous mixture of polysaccharide chains that vary in their affinity for antithrombin III and thus in their potency as anticoagtilants. They observed that 85% of the anticoagulent activity of porcine intestinal mucosal heparin resides in 30% of the mass and that two-thirds of the material is virtually inactive as an anticoagulant. Confirmation of this report was provided by Andersson et al. (32) and by Hook et al. (33) . Subsequently, Rosenberg and Lam (34) examined the structure of heparin fractions of 7,000 mol wt with high and low anticoagulant activity and demonstrated subtle differences in primary structure.
We undertook to study the reactivity with blood platelets of different subfractions of heparin, separated on the basis of molecular weight and according to antithrombin binding capacity. Different subfractions of heparin were found to interact with platelets to different degrees, which did not parallel the anticoagullant activity of the preparations.
METHODS
Collection of blood and preparation of citrated PRP and platelet-poor (platelet count <10,000/pA) plasma (PPP) were as previously described (35) . In some experiments, platelets were separated from plasma by filtration through a column of Sepharose 2B (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) by the technique of Tangen et al. (36) as modified by Lindon et al. (37) and were suspended in Tyrode's buffer, pH 7.4, containing 1 mg/ml glucose and 10.9 mNI trisodium citrate (gel filtered platelets). Apyrase, 200 gg/ml (see below), was added to the gel filtered platelet suispension to prevent "spontaneous aggregation" (presumably from ADP in the suspending medium) on stirring.
For some experiments, platelets were washed on a discontinuous stepwise bovine albumin gradient ( (43) . The '4C-labeled platelets in PRP or GFP wvere then exposed to 5 ,um/ml thrombin or "stock" heparin for 15 (44) . The resultant products attained maximal anticoagulant potency when molar ratios of inhibitor to mucopolysaccharide were set at <0.10. Further reductionis in this parameter to 0.03 or less did not result in the isolation of heparin species with higher biologic activities. Therefore, the molar ratios ofantithrombin to mucopolysaccharide were maintained at 0.08:0.10 for all stubsequent separationis of high activity material, which represented -25% of the heparin wvith high aniticoagtilanit activity and 8-10% of the entire pool. Low activity mucopolysaccharide was prepared in a similar manner but used a tw.o-to threefold molar excess of antithrombin to heparin. Material able to interact wvith antithrombin III (AT) (i.e., moderate anticoagulant activity) w%as discarded, whereas mucopolysaccharide unable to bind to the inhibitor was harvested. The high activity and low, activity produicts wvere rechromiiatographed onl Heparin and Platelet Aggregation columns of Sephadex G-100 (0.55 x 180 cm) at flow rates of 4 ml/h. The column matrix was previously equilibrated with 0.5 M NaCl in 0.01 M Tris-HCl, pH 7.5, and calibrated with heparin standards of known molecular size that had been studied by analytical ultracentrifugation and light scattering. Each of the high molecular weight or low molecular weight fractions appeared to be homogeneous. For comparison, a single lot of pharmaceutical grade porcine mucosal heparin was obtained from commercial sources (Panheparin, Abbott Laboratories, North Chicago, Ill.; lot number 26-428-DB, 1,000 U/ml, containing 0.9% benzyl alcohol as a preservative). This is referred to as "stock heparin."
The anticoagulant potency of heparin fractions was estimated in terms of their ability to accelerate the interaction of antithrombin with thrombin compared with a heparin standard of known U. S. Pharmacopeia potency, according to a previously described technique (31) .
Prostaglandins El and I2 were obtained from Dr. John Pike, Upjohn Co., Kalamazoo, Mich. N-amylthio-5'-AMP was obtained from Dr. K. Kikugawa, Kohjin Co., Osaka, Japan. Hirudin was purchased from Pentapharm Ltd., Basle, Switzerland, and was used without further purification. Potato apyrase was obtained from Sigma Chemical Co. and was further purified on a fetuin-agarose column to remove platelet-aggregating lectins according to the method of Whigham et al. (45) . Ristocetin was purchased from Pacific Hemostasis Labs, Bakersfield, Calif.
Scanning electron microscopy was performed on PRP samples by a previously described technique (46) .
AT was purified by affinity chromatography on heparinSepharose according to the method of Rosenberg and Damus (47) . It was assayed by radioimmunoassay using antibodies raised in goats against purified antithrombin. Goat immunoglobulin (Ig)G was supplied by Miles Laboratories, Inc., Miles Research Products, Elkhart, Ind., and anti-goat IgG serum prepared in rabbits was supplied by Atlantic Antibodies, Westbrook, Maine. Bound and unbound radioactivity was separated using a double antibody technique. Radiolabeled AT was prepared by chloramine T iodination (48) .
Antithrombin-poor plasma was prepared by passing.citrated PPP through a column (1.8 cm Diam and 3.5 cm long) of heparin-agarose gel prepared by the technique of Lindon et al. (46) . Passage of 100 ml of plasma through the column lowered its content of AT to <8 ,ug/ml in a typical experiment. Antithrombin-poor PRP was then prepared by gel filtration of albumin-washed platelets in Tyrode's buffer through a Sepharose 2B column previously equilibrated with two column volumes of antithrombin-poor PPP from the same donor. Platelets were thus suspended in autologous plasma depleted of antithrombin or other proteins that adhered to heparin but otherwise intact (49) . Preparation of the antithrombin-poor plasma occupied 2-3 h, so a fresh blood sample was obtained for preparation of the albumin-washed platelet suspension.
Statistical analysis was performed on the PROPHET System, a national computer resource sponsored by the Chemical/ 
RESULTS
When 10 ug/ml pharmaceutical grade commercial heparin, stock heparin, was added to citrated PRP at 370C, platelet aggregation in varying degrees was always demonstrable, provided the scale of the aggregometer recorder was expanded (details in Methods). Examination of the specimens by phase microscopy confirmed the presence of small platelet aggregates. The process did not reverse despite continued stirring in the aggregometer for up to 30 min. There was no release of [14C]serotonin or of ,3-thromboglobulin into the plasma in most experiments, but in PRP from a few donors (<5% of experiments), heparin induced twophase aggregation similar to that induced by ADP, and serotonin release was observed. Fig. 1 but not to the same extent. The high molecular weight fractions could be subdivided into preparations with either high or low antithrombin affinity (Table I) , which were approximately equal in their capacity to enhance the platelet response to other aggregating agents (Table  II) . Thus the reactivity with platelets did not parallel the anticoagulant activity. Among the low molectular weight fractions, those with low antithrombin affinity were as reactive with platelets as the high molecular weight fractions. However, the low molecular weight fractions of low antithrombin affinity were significantly more potent in enhancing aggregation and serotonin release than were the low molecular weight fractions of high antithrombin affinity (Table II ). An inverse relationship of anticoagulant activity and platelet reactivity in the low molecular weight fractions was also observed with enhancement of aggregation induced by epinephrine and collagen. As with the stock heparin, addition of the heparin fractions to citrated PRP led to platelet aggregation, which ocecurred without apparent shape change. The sensitivity to heparin-induced platelet aggregation varied widely fromi) blood donor to blood donor. A typical dose-response curve with a high molecular weight fraction of low antithrombin affinity is shown in Fig. 3 . The low molecular weight fractions were significantly less active in induction of platelet aggregation than were the higher molecular weight fractions (Table III) . Among the high molecular weight fractions, preparations of high and low affinity for antithrombin were not siginificantly different in their effectiveness as inducers of platelet aggregation. However, as was the (Fig. 4) .
Platelets fixed in formaldehyde are known to be aggregated by ristocetin (53 4 Platelets were washed by centrifugation on an albumin gradient and then passed through a Sepharose gel column (Methods) previously filled with PPP from the same blood donor who provided the platelets or with dilutions of PPP in varying quantities of Tyrode's solution with citrate and glucose. Thus the platelets were ultimately suspended in their own plasma ("reconstituted PRP") or in a plasma/ Tyrode's mixture containing 0, 25, 50, or 75% PPP. Heparin (high molecular weight-low antithrombin affinity; HMW-LAT), 10 ,g/ml, or ristocetin, 1.4 mg/ml, vas then added in an aggregometer at 37°C with stirring. Recorder scale was expanded as in Fig. 3 . Platelet counts in reconstituted samples were 141,000± +13,960 SD/ILA. platelet reactions (54) . This compound, which at a concentration of 0.05 mM inhibits both the primary and secondary phase of aggregation produced by ADP but only the second phase of aggregation induced by epinephrine or thrombin, had no effect on the aggregation of platelets iniduced in PRP by heparini firactions.
Another inhibitor of ADP-induced platelet reactions, apyrase, which hydrolyses ADP and blocks aggregation customarily attributed to platelet-derived ADP (55) , also failed to inhibit platelet aggregation induced in citrated PRP by heparin. At concentrations of 210-350 ,ug/ml, apyrase strongly inhibited both the first and second phases of the platelet aggregation response to ADP, but there was no effect on heparin-induced platelet clumping.
The effect of substances that increase platelet cyclic AMP on heparin's enhancement of the platelet response to other stimuli could not be studied because of direct inhibition of the primary response to the aggregating agent. It was, however, possible to study the enhancement of platelet activity in the presence of aspirin and other nonsteroidal antiinflammatory agents that inhibit only the second phase of platelet aggregation and serotonin secretion by inhibition of platelet cyclooxygenase, and do not prevent so-called "primary aggregation." Addition of stock heparin or heparin fractions to citrated PRP from a subject who had received 0.9 g aspirin 3 h earlier significantly reduced the defect in ADP-induced aggregation (Fig. 5) . Enhancement of ADP-induced platelet clumping by heparin was evident despite the ingestion of aspirin; there was no amelioration of the defect in serotonin release because of aspirin ingestion.
Heparin activates lipoprotein lipase derived from endothelial cells or liver (56) , and we considered the possibility that heparin might also activate platelet Heparin phospholipases, with subsequent formation o glandin endoperoxides leading to platelet aggr After addition of stock heparin or the heparin I to platelets in PRP or GFP labeled with [14( donic acid, there was no evidence of phosp] activation. In a typical experiment, 86% of the was incorporated by the platelets, and 22%
leased by thrombin and recovered in the aram acid spot after thin-layer chromatography. In t experiment, the arachidonic spot in a control (no thrombin) contained 12% of the 14C, and not increased by addition of heparin. Because enhancement by heparin of plat activity appeared to be more vigorous with lecular weight heparin fractions of low antit] affinity than with fractions of similar molecula with high affinity for antithrombin, it seemed that reaction of the heparin with AT inhibited platelet interaction. Analogous observations ha made concerning the behavior of some heparii surfaces (48) . To investigate this question, I were washed on an albumin gradient and we] pended either in citrated PPP that had been depleted of AT by passage through a heparin-Sepharose column (see Methods) or in normal PPP from the same donor. In reconstituted normal PRP, low molecular-weight heparin of high antithrombin affinity was significantly less active in enhancement of ADP-induced aggregation than were the other fractions, but in antithrombinpoor plasma, the heparin fractions were indistinguishable (Table IV) . When purified antithrombin was added back to the antithrombin-poor plasma (final concentration 200 ,ug/ml), the low molecular weight high affinity fraction once more became less reactive than the other [D] fractions.
DISCUSSION
We have shown that porcine mucosal heparin at a concentration of 10 ,ug/ml or less induces platelet aggregation in citrated PRP, but not in a suspension in Tyrode's buffer of platelets washed by centrifugation through an albumin gradient and then by gel filtration. Heparin also enhances aggregation and serotonin release induced by other agents. Platelet aggregation by heparin is blocked by EDTA and by substances that elevate platelet cyclic AMP but not by inhibitors of arachidonic ntrol) (A) acid cyclooxygenase or by hirudin. The platelet reeight-low sponse to heparin does not seem to require the involveted 0ro. g ment of ADP, because it is not inhibited by N-amylthioited (C). 5'-AMP or apyrase. )P), ADP These conclusions are to be contrasted with those of r aspirin Eika (28, 57) We found high molecular weight fractions to be more active than low molecular weight fractions in induction of platelet aggregation and in enhancement of aggregation induced by other agonists. Within a fraction of given molecular weight, platelet reactivity did not parallel anticoagulant activity. In high molecular weight fractions, antithrombin affinity appeared to have no relation to platelet reactivity. In low molecular weight preparations, there was a roughly reciprocal relationship between potency in induction of platelet aggregation or in enhancement of platelet aggregation by other agonists and antithrombin binding affinity, low affinity fractions being significantly more reactive toward platelets than high affinity fractions. Eika (62) reported that chemical alterations of heparin altered its anticoagulant effectiveness and platelet reactivity in parallel, but his heparin preparation was composed of a heterogeneous population of heparin molecules. His conclusion does not appear to be true for fractions of uniform molecular weight.
In PRP depleted of AT, low molecular weight heparin fractions ofhigh or low AT affinity were equivalent in enhancement of ADP-induced aggregation, but when the AT concentration was restored by adding back purified AT, a difference in behavior of the two fractions reappeared, comparable to the difference in normal PRP. These results suggest that antithrombin inhibits heparin-platelet interactions. Shanberge et al. (63) have reported that platelets bind heparin but not heparin-antithrombin complexes. Inhibition by antithrombin of heparin-induced reactions of platelets was also suggested in studies by Lindon et These observations are consistent with the existence of two types of binding sites on the heparin molecule; one that binds either to AT or to platelets but has a higher affinity for the former, and a second, perhaps the balance of the molecule, that binds preferentially to platelets. In the heparin fractions of low molecular weight, the former binding sites would appear to predominate in the high antithrombin affinity subfractions, so that, if exposed to antithrombin, these molecules are unlikely to react with platelets. The low antithrombin affinity subfractions of low molecular weight, whose few antithrombin binding sites may in fact be the result of contamination, react more strongly with platelets. In the high molecular weight heparin fractions, the molecules are apparently large enough to offer ample sites for reaction with platelets, regardless of the presence or absence of additional sites that bind antithrombin.
The failure ofheparin to aggregate platelets suspended in a buffer after albumin washing and gel filtration suggests a requirement for a plasma cofactor. Heparininduced platelet aggregation thus resembles platelet clumping induced by the antibiotic ristocetin, according to mechanisms proposed by Coller and Gralnick (65) . However, the plasma factor involved appears to be different from von Willebrand's factor, the plasma component required by ristocetin. Heparin-induced platelet aggregation is severely depressed in a solution of 25% PPP in Tyrode's buffer and does not occur with formaldehyde-fixed platelets, although these conditions support a vigorous platelet response to ristocetin.
Two thrombocytopenic syndromes have been described in patients receiving heparin: a transient, usually minor, reduction in platelet count occurring shortly after each intravenous injection, and a more severe sustained thrombopenia occurring 5-9 d after the initiation of heparin therapy. The former problem is reported to be almost universally present among patients who receive heparin (7). It seems likely that the fall in platelet count that immediately follows an injection of heparin results from sequestration of platelets aggregated by the mechanism described in this report. A similar process may be involved in cases of arterial embolism attributed to heparin therapy (15) (16) (17) .
Because low molecular weight heparin fractions of Heparin and Platelet Aggregation 71 high antithrombin affinity appear to have reduced reactivity with platelets, an improvement in clinical anticoaguilant therapy could probably be achieved by use of such fractions, which would be expected to maximize anticoagulant potency with a minimum of undesirable side effects on platelets. Such a prospect also offers hope for an improvement in the blood compatibility of heparin-coated artificial surfaces intended to function as thrombo-resistant materials in prosthetic devices such as artificial heart valves or pump oxygenators for cardiopulmonary bypass.
